Pharma giant Pfizer is opting for a massive foray into generic production. It has entered into a series of agreements with the India-based Aurobindo Pharma.
The deal will enable the company to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the United States and Europe, marking further progress in its Established Products Business Unit strategy, launched last year.
Read more: Pfizer Opts for Massive Generic Production | MedIndia http://www.medindia.net/news/Pfizer-Opts-for-Massive-Generic-Production-48210-1.htm#ixzz1oeRpVsnp
περισσότερα ΕΔΩ
The deal will enable the company to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the United States and Europe, marking further progress in its Established Products Business Unit strategy, launched last year.
Read more: Pfizer Opts for Massive Generic Production | MedIndia http://www.medindia.net/news/Pfizer-Opts-for-Massive-Generic-Production-48210-1.htm#ixzz1oeRpVsnp
περισσότερα ΕΔΩ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου